Economic burden of uncomplicated urinary tract infections: Direct, indirect and intangible costs

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 5, Issue 4, 2005, Pages 457-466

  Keating, Karen N ^a   Perfetto, Eleanor M ^b   Subedi, Prasun ^c  

^a BAYER CORPORATION   (United States)

^b Weinberg Group Inc   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Antibiotic therapy; Direct medical costs; Indirect costs; Intangible costs; Uncomplicated urinary tract infection

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; COTRIMOXAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HOSPITAL COST; HUMAN; MEDICAL RESEARCH; PATIENT COMPLIANCE; PREVALENCE; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY; TREATMENT FAILURE; TREATMENT PLANNING; URINARY TRACT INFECTION;

EID: 24744440589     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.5.4.457     Document Type: Review

References (24)

1. Nicolle LE. Epidemiology of urinary tract infections. Infect. Med. 18, 153-162 (2001).
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis. Mon. 49, 53-70 (2003).
3. Foxman B, Barlow R, D'Arcy H et al. Urinary tract infection: self-reported incidence and associated costs. Ann. Epidemiol. 10(8), 509-515 (2000).
4. Foxman B, Brown P. Epidemiology of urinary tract infections. Transmission and risk factors, incidence and costs. Infect. Dis. Clin. North Am. 17, 227-241 (2003).
5. Sotelo T, Westney OL. Recurrent urinary tract infections in women. Curr. Womens Health Rep. 3, 313-318 (2003).
6. Schappert SM. Ambulatory care visits to physician offices, hospital out-patient departments, and emergency departments US, 1997. Vital Health Stat. 143(13), i-iv, 1-39 (1999).
7. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med. 113(1A), S5-S13 (2002).
8. Hooton T. Recurrent urinary tract infection in women. Int. J. Antimicrob. Agents 17, 259-268 (2001).
9. Rosenberg M. Pharmacoeconomics of treating uncomplicated urinary tract infections. Int. J. Antimicrob. Agents 11, 247-251 (1999).
10. Gold MR, Siegel JE, Russle LB, Weinsteing MC. In: Cost-Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
11. Vogenberg, FR. In: Introduction to Applied Pharmacoeconomics. McGraw-Hill, NY, USA (2001).
12. Baerheim A, Digranes A, Jureen R, Malterud K. Generalized symptoms in adult women with acute uncomplicated lower urinary tract infection: an observational study. MedGenMed. 50), 1 (2003).
13. Colgan R, Keating K, Dougouih M. Survey of symptom burden in women with uncomplicated urinary tract infections. Clin. Drug Invest. 24(1), 55-60 (2004).
14. Baerheim A, Digranes A, Hunkskaar S. Equal symptomatic outcome after antibacterial treatment of acute lower urinary tract infection and the acute urethral syndrome in adult women. Scand. J. Prim. Health Care 17, 170-173 (1999).
15. Ellis A. Quality of life in women with urinary tract infections: is benign disease a misnomer? J. Am. Board Fam. Pract. 13(6), 392-397 (2000).
16. Foxman B, Frerichs R. Epidemiology of urinary tract infection: I. Diaphragm use and sexual intercourse. Am. J. Pub. Health 75, 1308-1313 (1985).
17. Klimberg I, Shockey G, Ellison H et al. Time to symptom relief for uncomplicated urinary tract infection treated with extended-release ciprofloxacin: a prospective, open-label, uncontrolled primary care study. Curr. Med. Res. Opin. 21(8), 1241-1250 (2005).
18. Malterud K, Baerheim A. Peeing barbed wire: symptom experiences in women with lower urinary tract infection. Scand. J. Prim. Health Care 17, 49-53 (1999).
19. Moller L, Lose G, Jorgensen T. The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age. Acta Obstet. Gynecol. Scand. 79, 298-305 (2000).
20. Hooton TM. The current management strategies for community acquired urinary tract infection. Infect. Dis. Clin. North Am. 17, 303-332 (2003).
21. Perfetto EM, Keating K, Merchant S, Nichols B. Acute uncomplicated UTI and E. coli resistance: implications for first-line empirical antibiotic therapy. J. Manag. Care Pharm. 10(1), 17-25 (2004).
22. Katz J, Melzack R. Measurement of pain. Surg. Clin. North Am. 79(2), 231-252 (1999).
23. Blondeau J. Current issues in the management of urinary tract infections. Extended-release ciprofloxacin as a novel treatment option. Drugs 64(6), 611-628 (2004).
24. Sanson-Fischer R, Bowman J, Armstrong S. Factors affecting nonadherence with antibiotics. Diagn. Microbiol. Infect. Dis. 15, S103-S109 (1992).